Proton pump inhibitors and the risk of pneumonia: how dangerous is it to use these drugs during the COVID-19 pandemic?


DOI: https://dx.doi.org/10.18565/therapy.2021.1.78-82

Moroz E.V., Karateev A.E.

1) N.N. Burdenko Мain Military Clinical Hospital of the Ministry of Defence of Russia, Moscow; 2) V.A. Nasonova Research Institute of Rheumatology, Moscow
Abstract. The problem of the COVID-19 pandemic is a priority for the global medical community. One of the central themes discussed in the light of optimizing disease prevention is potential negative impact of a number widely used in therapeutic practice medicines on COVID-19 development. Thus, the subject of discussion was the safety of proton pump inhibitors (PPIs): there is information that their use is associated with an increased risk of community-acquired pneumonia development. In recent months, a number of studies demonstrating the connection between regular PPIs’ use and the risk of severe COVID-19 forms development have been published. However, in many situations, the use of this class of medicines is vital. Consequentially, the prescription of thesemedicines during the COVID-19 pandemic should be carried out for clear indications, after carefully assessing the possible benefits and potential harm.
Keywords: COVID-19, proton pump inhibitors, complications, pneumonia

Literature



  1. Насонов Е.Л. Коронавирусная болезнь – 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020; 2: 123–132. [Nasonov E.L. Coronavirus disease 2019 (COVID-19): A rheumatologist’s thoughts. Nauchno-prakticheskaya revmatologiya = Rheumatology science and practice. 2020; 2: 123–132 (In Russ.)]. Doi: https://doi.org/10.14412/1995-4484-2020-123-132.

  2. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available at: https://gisanddata.maps.arcgis.com/apps/opsdashboard (date of access – 20.01.2021).

  3. Micallef J., Soeiro T., Jonville-Bera A.P. French Society of Pharmacology, Therapeutics (SFPT). Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. Therapie. 2020; 75(4): 355–62. doi: 10.1016/j.therap.2020.05.003.

  4. Wong M.C.S., Wong S., Huang J., Yan B. Relating angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID-19. ESC Heart Fail. 2020; 7(5): 3119–23. doi: 10.1002/ehf2.12952.

  5. Budhathoki P., Shrestha D.B., Rawal E., Khadka S. Corticosteroids in COVID-19: Is it Rational? A systematic review and meta-analysis. SN Compr Clin Med. 2020: 1–21. doi: 10.1007/s42399-020-00515-6. Online ahead of print.

  6. Sadeghinia A., Daneshpazhooh M. Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review. Dermatol Ther. 2020: e14498. doi: 10.1111/dth.14498. Online ahead of print.

  7. Strand D.S., Kim D., Peura D.A. 25 Years of proton pump inhibitors: A comprehensive review. Gut Liver. 2017; 11(1): 27–37. doi: 10.5009/gnl15502.

  8. Spechler S.J. Proton pump inhibitors: What the internist needs to know. Med Clin North Am. 2019; 103(1): 1–14. doi: 10.1016/j.mcna.2018.08.001.

  9. Savarino V., Marabotto E., Furnari M. et al. Latest insights into the hot question of proton pump inhibitor safety – a narrative review. Dig Liver Dis. 2020; 52(8): 842–52. doi: 10.1016/j.dld.2020.04.020.

  10. Jaynes M., Kumar A.B. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf. 2018; 10: 2042098618809927. doi: 10.1177/2042098618809927.

  11. Maes M.L., Fixen D.R., Linnebur S.A. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017; 8(9): 273–97. doi: 10.1177/2042098617715381.

  12. Agastya G., West B.C., Callahan J.M. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol. 2000; 22(2): 357–72. doi: 10.3109/08923970009016425.

  13. Martins de Oliveira R., Antunes E., Pedrazzoli J. Jr, Gambero A. The inhibitory effects of H+ K+ ATPase inhibitors on human neutrophils in vitro: restoration by a K+ ionophore. Inflamm Res. 2007; 56(3): 105–11. doi: 10.1007/s00011-006-6127-6.

  14. Zedtwitz-Liebenstein K., Wenisch C., Patruta S. et al. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002; 30(5): 1118–22. doi: 10.1097/00003246-200205000-00026.

  15. Gilman-Sachs А., Tikoo А., Akman-Anderson L. et al. Expression and role of a2 vacuolar-ATPase (a2V) in trafficking of human neutrophil granules and exocytosis. J Leukoc Biol. 2015; 97(6): 1121–31. doi: 10.1189/jlb.3A1214-620RR.

  16. Lambert A.A., Lam J.O., Paik J.J. et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015; 10(6): e0128004. doi: 10.1371/journal.pone.0128004.

  17. 17. Zirk-Sadowski J., Masoli J.A., Delgado J. et al. Proton-pump inhibitors and long-term risk of community-acquired pneumonia in older adults. J Am Geriatr Soc. 2018; 66(7): 1332–38. doi: 10.1111/jgs.15385.

  18. Othman F., Crooks C.J., Card T.R. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ. 2016; 355: i5813. doi: 10.1136/bmj.i5813.

  19. Johnson D.A., Katz P.O., Armstrong D. et al. The safety of appropriate use of over-the-counter proton pump inhibitors: An evidence-based review and Delphi consensus. Drugs. 2017; 77(5): 547–61. doi: 10.1007/s40265-017-0712-6.

  20. Almario C.V., Chey W.D., Spiegel B.M.R. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. 2020; 115(10): 1707–15. doi: 10.14309/ajg.0000000000000798.

  21. Lee S.W., Ha E.K., Yeniova A.O. et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021; 70(1): 76–84. doi: 10.1136/gutjnl-2020-322248.

  22. Luxenburger H., Sturm L., Biever P. et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor? J Intern Med. 2021; 289(1): 121–24. doi: 10.1111/joim.13121.

  23. Ramachandran P., Perisetti A., Gajendran M. et al. Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19. Eur J Gastroenterol Hepatol. 2020. doi: 10.1097/MEG.0000000000002013. Online ahead of print.

  24. McKeigue P.M., Kennedy S., Weir A. et al. Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study. medRxiv. 2020. doi: 10.1101/2020.07.23.20160747.

  25. Li G.F., An X.X., Yu Y. et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut. 2020: gutjnl-2020-323366. doi: 10.1136/gutjnl-2020-323366. Online ahead of print.

  26. Hariyanto T.I., Prasetya I.B., Kurniawan A. Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection. Dig Liver Dis. 2020; 52(12): 1410–12. doi: 10.1016/j.dld.2020.10.001.

  27. Kow C.S., Hasan S.S. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis. J Intern Med. 2021; 289(1): 125–28. doi: 10.1111/joim.13183.

  28. Patel P., Sengupta N. PPIs and Beyond: A Framework for managing anticoagulation-related gastrointestinal bleeding in the era of COVID-19. Dig Dis Sci. 2020; 65(8): 2181–86. doi: 10.1007/s10620-020-06408-x.

  29. Gadiparthi C., Perisetti A., Sayana H. et al. Gastrointestinal bleeding in patients with severe SARS-CoV-2. Am J Gastroenterol. 2020; 115(8): 1283–85. doi: 10.14309/ajg.0000000000000719.

  30. Lanas-Gimeno A., Hijos G., Lanas A. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opin Drug Saf. 2019; 18(11): 1043–53. doi: 10.1080/14740338.2019.1664470.

  31. Boghossian T.A., Rashid F.J., Thompson W. et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017; 3(3): CD011969. doi: 10.1002/14651858.CD011969.pub2.

  32. Helgadottir H., Bjornsson E.S. Problems associated with deprescribing of proton pump inhibitors. Int J Mol Sci. 2019; 20(21): 5469. doi: 10.3390/ijms20215469.


About the Autors


Elena V. Moroz, PhD, head of gastroenterological Department of N.N. Burdenko Мain Military Clinical Hospital of the Ministry of Defence of Russia. Address: 105229, Moscow, 3 Gospital`naya Sq. Tel.: +7 (499) 263-55-55 (add. 5100). E-mail: evmoroz777@rambler.ru. ORCID: 0000-0003-0439-6287
Andrey E. Karateev, MD, head of the laboratory of pathophysiology of clinical polymorphism of musculoskeletal diseases of V.A. Nasonova Research Institute of Rheumatology. Address: 115522, Moscow, 34A Kashirskoe highway. Tel.: +7 (910) 404-11-60. E-mail: aekarat@yandex.ru. ORCID: 0000-0002-1391-0711


Бионика Медиа